Group 1 - The core viewpoint of the article highlights TE HEALTHCARE's financial performance for the year ending December 31, 2025, showing a significant increase in revenue driven by B2C momentum [1] - The company's revenue reached HKD 102 million, representing an 18% growth compared to HKD 86.49 million in 2024 [1] - Gross profit was HKD 39.53 million with a gross margin of 38.7%, slightly down from HKD 34.03 million and a margin of 39.4% in 2024 [1] Group 2 - Administrative and other operating expenses increased by 45% to HKD 44.966 million, attributed to marketing and legal/professional fees related to B2C expansion and corporate activities [1] - The company reported a pre-tax loss of HKD 6.66 million, contrasting with a pre-tax profit of HKD 12.59 million in 2024 [1] - The net loss attributable to owners was HKD 7.114 million, compared to a net profit of HKD 11.338 million in 2024 [1]

Core Viewpoint - The company, Jinju Group, will hold a board meeting on March 30, 2026, to review and potentially approve the financial performance for the fiscal year ending December 31, 2025, along with related announcements [1] Summary by Categories - **Company Announcement** - Jinju Group has announced a board meeting scheduled for March 30, 2026 [1] - The meeting will focus on reviewing and approving the financial results for the fiscal year ending December 31, 2025 [1]

Core Viewpoint - The company, Huayu Energy (01251.HK), will hold a board meeting on March 26, 2026, to consider and approve the annual performance for the year ending December 31, 2025, and to discuss the potential declaration of a final dividend, if applicable [1] Group 1 - The board meeting is scheduled for March 26, 2026 [1] - The meeting will focus on the annual performance for the fiscal year ending December 31, 2025 [1] - The board will also consider the declaration of a final dividend [1]

Core Viewpoint - The company, Jinju Group (02009.HK), will hold a board meeting on March 30, 2026, to review and potentially approve the financial performance for the fiscal year ending December 31, 2025, along with related announcements [1] Group 1 - The board meeting is scheduled for March 30, 2026 [1] - The meeting will focus on the financial results of the company and its subsidiaries for the fiscal year ending December 31, 2025 [1] - The company will consider the publication of related proposals during the meeting [1]

Core Viewpoint - China Biologic Products Holdings (01177.HK) announced that it will hold a board meeting on March 26, 2026, to approve the annual results for the year ending December 31, 2025, and to consider the proposal for the final dividend distribution, if any [1] Group 1 - The board meeting is scheduled for March 26, 2026 [1] - The meeting will focus on approving the annual performance results for the year ending December 31, 2025 [1] - The company will also consider the proposal for the final dividend distribution during this meeting [1]

Group 1 - Southbound funds recorded a net sell of HKD 1.25 billion in Hong Kong stocks on March 16, with notable net purchases in Tencent Holdings (HKD 2.287 billion), Alibaba-W (HKD 706 million), BYD Company (HKD 586 million), and Geely Automobile (HKD 442 million) [1] - The net sell was primarily driven by the iShares Asia 50 ETF, which saw a net sell of HKD 3.574 billion, and Xiaomi Group-W with HKD 844 million [1][3] - Southbound funds have consistently net bought China National Offshore Oil Corporation (CNOOC) for four consecutive days, totaling HKD 3.38424 billion [1] Group 2 - Tencent Holdings experienced a price increase of 2.0% with a net buy of HKD 4.21 billion, while Alibaba-W saw a 1.1% increase with a net buy of HKD 3.55 billion [3] - BYD Company had a significant price increase of 7.8% with a net buy of HKD 4.37 billion, and Geely Automobile increased by 3.6% with a net buy of HKD 4.42 billion [3] - The overall trading volume for the stocks mentioned indicates a mixed performance, with some stocks like Xiaomi Group-W and SMIC showing negative net buy figures [3]

Core Viewpoint - Shougang Resources (00639.HK) will hold a board meeting on March 26, 2026, to approve the annual results for the year ending December 31, 2025, and consider the proposal for the final dividend distribution [1] Group 1 - The board meeting is scheduled for March 26, 2026 [1] - The meeting will focus on approving the annual performance of the company and its subsidiaries for the year ending December 31, 2025 [1] - The board will also consider the proposal for the final dividend distribution if appropriate [1]

格隆汇3月16日丨中国飞鹤(06186.HK)发布公告，谨定于2026年3月26日（星期四）举行董事会会议，以 考虑及通过集团截至2025年12月31日止的全年业绩，及建议的末期股息（如有），以及处理其他事项。 ...

Group 1 - Shangri-La Asia (00069.HK) announced the appointment of Tsai Yuanwen as an independent non-executive director and a member of the audit and risk committee, effective March 16, 2026 [1]

Group 1 - The company, 医脉通 (02192.HK), announced that it will hold a board meeting on March 26, 2026, to consider and approve the annual performance for the year ending December 31, 2025, along with its release [1] - The board will also consider the distribution of a final dividend, if applicable [1]